Dual protease inhibitor (PI) therapy and the inclusion of ritonavir do not appear to increase the incidence of hepatotoxicity

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1340, 2002-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual-protease inhibitor (PI) therapy was associated with an increased rate of virological failure

By  

Inpharma, Vol. 1, Iss. 1625, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline

By  

Reactions Weekly, Vol. 1, Iss. 1188, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Dual protease inhibitor therapy in the management of the HIV-1

By Yu K.   Daar E.S.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 7, 2000-12 ,pp. : 1331-1342

Informa Healthcare

Access to resources Recommend Favorite

Tipranavir: A Ritonavir-Boosted Protease Inhibitor

By Croom Katherine F.   Keam Susan J.  

Drugs, Vol. 65, Iss. 12, 2005-01 ,pp. : 1669-1677

Adis International

Access to resources Recommend Favorite